Versant Venture Capital
Venture capitalSan Francisco · 11 people tracked
Find your way into Versant Venture Capital
Fund manager profile
Versant Venture Capital is a venture fund manager based in San Francisco. SEC filings show 5 venture funds on record, most recently Versant Venture Capital IX, L.P. ($600.4M offering) filed April 2023.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 11 people
from public directoriesWhat they invest in
from 5 of 6 portfolio companiesBiotech ×5Healthtech ×2Medical Devices ×1
HQs:United States×4
Investments · 6 tracked
founders shown can be your intro pathBy year:2023 · 12020 · 22016 · 12015 · 15 dated
Black Diamond Therapeutics develops small-molecule kinase inhibitors targeting families of oncogenic mutations across cancer types, including its lead candidate silevertinib for EGFR-mutant lung cancer and glioblastoma.
Elizabeth Buck(Chief Scientific Officer)Brent Hatzis-Schoch(Chief Operating Officer and General Counsel)inSergey Yurasov(Chief Medical Officer)inMelanie Morrison(Chief Development Officer)
Co-investorsLAVLilly Asia VenturesNew Enterprise Associates (NEA)Nextech InvestNSG VenturesRA Capital+3 more
858 Therapeutics is a clinical-stage biotechnology company developing targeted cancer therapies that act on tumor dependencies in DNA damage response (DDR) pathways.
BiotechHealthtechSan Diego, US
Stafford Jeffrey(Executive Officer, Director)inJames Veal(Executive Officer)Katherine Bell-McGuinn(Executive Officer)Joseph Leveque(Chief Medical Officer)
BoardMonal Mehta(Director)inAli Behbahani(Director)in
Board seatBradley J. BolzonClare Ozawa· per SEC Form D · $37.5M raise · filed Mar 2020
Co-investorsNew Enterprise Associates (NEA)Versant Ventures
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Aetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)inKaren Flick(General Counsel)in
Board seatClare OzawaThomas Woiwode· per SEC Form D · $70.1M raise · filed Sep 2021
Co-investorsREDMILEVersant VenturesBAM ElevateFranklin TempletonHBM Healthcare InvestmentsInvus+4 more
Santa Ana Bio develops engineered antibodies targeting immune system pathways to treat autoimmune and inflammatory diseases.
BiotechMedical DevicesAlameda, US
Peter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)Graham Lord(Scientific Founder)inAnsuman Satpathy(Scientific Founder)in
Board seatJerel DavisThomas Woiwode· per SEC Form D · $70.3M raise · filed Feb 2023
Co-investorsAccess BiotechnologyAndreessen HorowitzGV (Google Ventures)Versant Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
CRISPR Therapeutics AGInception IBD
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 1
IPOs and acquisitions across the tracked portfolioBlack Diamond Therapeutics, IncNASDAQ: BDTX
Portfolio news
latest coverage across their companies
Black Diamond Therapeutics, Inc · finance.yahoo.com · Sep 2, 2026
Lycia Therapeutics · intelligence360.news · Jul 22, 2026
Fund performance · per public LP disclosures
as of Jun 2020| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Versant Venture Capital I, L.P.LPs: The Regents of the University of California | 1999 | — | 10.2% | 2.02x | 2.02x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Black Diamond Therapeutics, Inc | 29.1% | $19.00 | Jan 2020 | $189.8M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- Where is Versant Venture Capital located?
- Versant Venture Capital is headquartered in San Francisco, US.